Roche’s Tecentriq joins UK’s early access to meds scheme
Roche’s Tecentriq has been accepted onto the UK’s Early Access to Medicines Scheme (EAMS), having picked up a positive scientific opinion from the Medicines and Healthcare products Regulatory Agency for the treatment of bladder cancer.
Read More
